Management of arrhythmias in heart failure.
The literature for coronary artery disease as well as ischemic and dilated cardiomyopathy suggests that ventricular arrhythmias and left ventricular dysfunction are independent risk factors for sudden death, but that the presence of organic heart disease provides the substrate for potentially lethal arrhythmias. Patients with a cardiomyopathy and ventricular tachycardia are at a high risk for sudden death as a group. The general risk, then, is high for the group with CHF and arrhythmias. The prognostic indices for hypertrophic cardiomyopathy are imprecise, but the risk for sudden death for the group is high in the young and remains high even among the adult survivors. Many conditions associated with CHF and its treatment may lead to arrhythmias and are potentially reversible. Most studies suggest that EPS and exercise provocation have limited power in predicting the risk to the individual patient. Therapeutically, reversible causes of arrhythmias should be sought and corrected. In general, antiarrhythmic drug therapy has been disappointing with adequate control being achieved in only about 30 per cent of patients and uncertainties about the effectiveness of such therapy in altering long-term prognosis. This is due to various causes including the inability to find an effective drug, problems with patient compliance, the failure of physicians to properly monitor drug levels, and changes in the anatomical and physiologic substrate due to disease and therapy. Surgical ablation or resection of arrhythmogenic foci is effective in selected patients. The AICD will become first-line therapy in patients at high risk for sudden death due to ventricular arrhythmias, with antiarrhythmic drugs and other approaches being used to minimize the frequency of the arrhythmias.